QQ客服 官方微博 反馈留言

	RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis
	Cosgriff T., Yang L., Alyasova A., Ye D., Karpenko A., Li H., Alekseev B., Xie L.-P., Kowalyszyn R.D., Karyakin O., Neron Y.V., Collins L.T., Brechenmacher T., Lin C., Morgan L., Motzer R.J.
刊名	Journal of Clinical Oncology
	2016
卷号	34
ISSN号	0732-183X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3628006
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Cosgriff T., Yang L., Alyasova A., Ye D., Karpenko A., Li H., Alekseev B., Xie L.-P., Kowalyszyn R.D., Karyakin O., Neron Y.V., Collins L.T., Brechenmacher T., Lin C., Morgan L., Motzer R.J.. RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis[J]. Journal of Clinical Oncology,2016,34.
APA	Cosgriff T., Yang L., Alyasova A., Ye D., Karpenko A., Li H., Alekseev B., Xie L.-P., Kowalyszyn R.D., Karyakin O., Neron Y.V., Collins L.T., Brechenmacher T., Lin C., Morgan L., Motzer R.J..(2016).RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.Journal of Clinical Oncology,34.
MLA	Cosgriff T., Yang L., Alyasova A., Ye D., Karpenko A., Li H., Alekseev B., Xie L.-P., Kowalyszyn R.D., Karyakin O., Neron Y.V., Collins L.T., Brechenmacher T., Lin C., Morgan L., Motzer R.J.."RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis".Journal of Clinical Oncology 34(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。